resTORbio, Inc.

United States

Show jobs for this employer

About resTORbio, Inc.

resTORbio, Inc., a subsidiary of PureTech Health (LSE: PRTC;, is developing medicines to treat aging-related diseases and conditions. resTORbio’s lead program is targeting the mechanistic target of rapamycin complex 1 (mTORC1) pathway to treat aging-related diseases and conditions with an initial focus on conditions caused by immunosenescence, the decline in immune function due to aging. resTORbio’s lead program is built upon two Phase 2 clinical studies demonstrating promising safety and efficacy results in almost 500 hundred elderly subjects. resTORbio is pursuing a pragmatic clinical development plan addressing areas of key unmet medical need in the aging population.
CEO: Chen Schor
CMO: Joan Mannick

35 articles about resTORbio, Inc.